Alpa Laboratories Limited (ALPA) AI Stock Analysis

Alpa Laboratories Limited

(NSE:ALPA)

Select Model

Rating:55Neutral

Price Target:INR 51.00▼(-2.63% Downside)

Action:reiterated

Date:09/06/26

The score is mainly supported by a very strong, low-debt balance sheet and expanding equity base, but is held back by recent operating deterioration and inconsistent revenue/margin trends. Technicals are weak with the stock trading below major moving averages and a negative MACD, and valuation is stretched at a ~37x P/E without a stated dividend yield.

Positive Factors

Low LeverageVery low leverage gives Alpa Laboratories financial resilience and reduces interest-related pressure on future earnings. The conservative capital structure also preserves flexibility to fund operations, withstand volatility, and pursue growth without relying heavily on external borrowing.

Negative Factors

Revenue DeclineThe latest revenue contraction indicates that recent expansion has not been consistent, making forward growth less predictable. A declining top line can reduce operating leverage, limit reinvestment capacity, and make it harder for the company to build durable scale across its pharmaceutical product portfolio.

Alpa Laboratories Limited (ALPA) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 1.06B
Dividend Yield: ―
Average Volume (3M): 4,616
Price to Earnings (P/E): 30.0
Beta (1Y): 1.49
Revenue Growth: 0.46%
EPS Growth: -83.31%
Country: India
Employees: 457
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Alpa Laboratories Limited Business Overview & Revenue Model

Company Description

Established in Indore, India in 1967, Alpa Laboratories Limited focuses on the manufacturing, marketing, and distribution of finished pharmaceutical products, both domestically within India and for export. The company offers a wide array of human-gra...

Alpa Laboratories Limited Financial Statement Overview

Summary

Strong balance sheet strength (very low leverage and steadily growing equity) supports financial resilience, but recent operating performance weakened materially (sharp margin compression and a revenue decline in the latest year). Cash flow is improving in 2026, yet cash conversion versus earnings remains weak and free cash flow has been volatile, reducing earnings quality and predictability.

Income Statement

58Neutral

Balance Sheet

86Very Positive

Cash Flow

54Neutral

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	1.16B	1.06B	1.12B	1.09B	924.10M	1.11B
Gross Profit	243.95M	136.09M	193.99M	188.90M	307.44M	344.08M
EBITDA	75.79M	190.47M	281.01M	229.96M	174.43M	214.31M
Net Income	43.78M	150.10M	195.03M	167.76M	125.83M	140.92M
Balance Sheet
Total Assets	0	2.42B	2.23B	1.82B	1.67B	1.55B
Cash, Cash Equivalents and Short-Term Investments	1.38B	1.38B	1.13B	928.54M	808.42M	702.74M
Total Debt	0	25.08M	343.00K	52.47M	23.04M	58.47M
Total Liabilities	-1.86B	558.64M	511.59M	304.62M	326.92M	335.08M
Stockholders Equity	1.86B	1.86B	1.71B	1.52B	1.35B	1.22B
Cash Flow
Free Cash Flow	89.97M	84.84M	-21.42M	-27.36M	77.78M	77.49M
Operating Cash Flow	106.65M	124.37M	92.37M	36.49M	89.04M	99.40M
Investing Cash Flow	-144.58M	-143.01M	-35.13M	-133.36M	21.27M	-156.10M
Financing Cash Flow	22.40M	24.80M	-52.47M	25.83M	-37.93M	54.42M

Alpa Laboratories Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price52.38

Price Trends

50DMA58.77Negative

100DMA63.40Negative

200DMA65.10Negative

Market Momentum

MACD-2.58Positive

RSI34.51Neutral

STOCH48.51Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALPA, the sentiment is Negative. The current price of 52.38 is below the 20-day moving average (MA) of 54.57, below the 50-day MA of 58.77, and below the 200-day MA of 65.10, indicating a bearish trend. The MACD of -2.58 indicates Positive momentum. The RSI at 34.51 is Neutral, neither overbought nor oversold. The STOCH value of 48.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALPA.

Alpa Laboratories Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:ALPA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:PAR	73Outperform	INR 1.41B	9.73	―	―	9.40%	34.12%
IN:BROOKS	61Neutral	INR 1.79B	13.49	―	―	-7.71%	927.75%
IN:BALPHARMA	58Neutral	INR 1.29B	18.03	―	1.47%	13.51%	-14.80%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:BIOFILCHEM	55Neutral	INR 471.94M	96.99	―	―	9.31%	-82.71%
IN:ALPA	55Neutral	INR 1.05B	29.99	―	―	0.46%	-83.31%
IN:NECLIFE	43Neutral	INR 2.00B	-0.90	―	―	-99.53%	-41.93%

* General Sector Average

Performance Comparison

IN:ALPA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:ALPA	Alpa Laboratories Limited	49.80	-38.96	-43.89%
IN:BALPHARMA	Bal Pharma Limited	81.20	0.66	0.82%
IN:BIOFILCHEM	Biofil Chemicals & Pharmaceuticals Ltd.	29.00	-10.60	-26.77%
IN:BROOKS	Brooks Laboratories Limited	60.85	-50.00	-45.11%
IN:NECLIFE	Nectar Lifesciences Ltd.	10.29	-3.87	-27.33%
IN:PAR	Par Drugs and Chemicals Limited	114.67	15.52	15.65%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026

Alpa Laboratories Limited AI Stock Analysis